Opinion|Videos|June 12, 2024
Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs
Health care professionals discuss the optimal timeline for collaborating with provider advocates to develop and implement protocols that facilitate patient access to prescription digital therapeutics (PDTs).
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Dr. Brixner: At what point(s) in the product lifecycle do clinicians want/need to receive education from PDT manufacturers to effectively learn about, prescribe, and manage these digital therapies?
- Is there a preference for this education to occur pre-approval, post-approval but pre-launch, at commercial launch, or continuously throughout the product’s market availability?
- Peterson: How do payers track and monitor prescribing and utilization patterns for covered PDTs?
- Have payers had to adjust policies after initial PDT adoption due to inappropriate prescribing or utilization issues?
- How do you see value-based or risk-based contracts evolving now that larger pharma manufacturers are developing and commercializing PDTs?
- In your experiences, how do the metrics used to evaluate the real-world performance of PDTs, such as engagement metrics and discontinuation rates, differ from the traditional metrics employed for molecular drug therapies?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5